Literature DB >> 32523890

High Expression of Interleukin-12A and Its Association with the Clinicopathology and Prognosis of Differentiated Thyroid Cancer.

Guo-Qiang Zhang1, Chen-Tian Shen1, Hong-Jun Song1, Zhong-Ling Qiu1, Quan-Yong Luo1.   

Abstract

BACKGROUND: The inflammatory microenvironment is closely related to the occurrence and development of cancer. Members of the interleukin-12 (IL-12) cytokine family play synergistic or antagonistic roles in the tumor microenvironment, in the form of classic heterodimers or newly discovered monomers or homodimers.
OBJECTIVE: The purpose of this study was to investigate the association between IL-12A and the clinicopathology and prognosis of differentiated thyroid cancer (DTC).
METHODS: A total of 101 pathologically confirmed DTC patients were included in this study. Immunohistochemistry was performed to assess IL-12A expression in DTC and corresponding paracancerous tissues. The associations of IL-12A with clinicopathology and prognosis were evaluated.
RESULTS: IL-12A was expressed in both normal thyroid tissues and DTC, but its expression level was significantly higher in DTC than in normal thyroid tissues (p < 0.001). IL-12A was positively correlated with tumor size (p = 0.027), risk stratification (p = 0.020), and TNM (Tumor-Node-Metastasis) stage (p = 0.024), but not with age, sex, pathological type, multifocality, extrathyroid extension, lymph node metastasis, and distant metastasis (all p > 0.05). Lymphocytic thyroiditis was found in 26/101 patients (25.7%), which was negatively associated with IL-12A expression (p = 0.018). Multivariate logistic regression analysis showed that risk stratification was the significant independent predictor of IL-12A expression. The rate of disease persistence or recurrence (P&R) was 13/101 (12.9%), and a positive relationship was found between IL-12A expression and P&R (p = 0.020). Disease-free survival was affected by factors such as tumor size, extrathyroid extension, tumor stage (T stage), and IL-12A expression, with p values of 0.006, 0.048, 0.002, and 0.012, respectively. Multivariate Cox proportional-hazards analysis showed that tumor size ≥2 cm (hazard ratio [HR] = 4.041 [95% CI: 1.144-14.274], p = 0.031) and high IL-12A expression (HR = 4.027 [95% CI 1.014-15.994], p = 0.049) were independent predictors of prognosis of DTC patients.
CONCLUSIONS: IL-12A is highly expressed in DTC and is associated with disease aggressiveness. In addition, IL-12A is an independent predictor of the outcome of DTC.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Differentiated thyroid cancer; Interleukin-12A; Prognosis

Year:  2020        PMID: 32523890      PMCID: PMC7265709          DOI: 10.1159/000505811

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  23 in total

1.  The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer.

Authors:  Meng-Feng Wu; Yun-Chi Wang; Hsin-Ting Li; Wei-Chun Chen; Cheng-Hsi Liao; Tzu-Ching Shih; Wen-Shin Chang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  Anticancer Res       Date:  2018-11       Impact factor: 2.480

2.  Interleukin 12 gene polymorphisms enhance gastric cancer risk in H pylori infected individuals.

Authors:  F Navaglia; D Basso; C-F Zambon; E Ponzano; L Caenazzo; N Gallo; A Falda; C Belluco; P Fogar; E Greco; F Di Mario; M Rugge; M Plebani
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

3.  IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer.

Authors:  Apostolos K Karagiannis; Anastassios Philippou; Sofia Tseleni-Balafouta; Evaggelos Zevolis; Theodora Nakouti; Maria Tsopanomichalou-Gklotsou; Vasilis Psarras; Michael Koutsilieris
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

4.  LYMPHOCYTIC THYROIDITIS IS ASSOCIATED WITH INCREASED NUMBER OF BENIGN CERVICAL NODES AND FEWER CENTRAL NECK COMPARTMENT METASTATIC LYMPH NODES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.

Authors:  Ines Donangelo; Ann E Walts; Catherine Bresee; Glenn D Braunstein
Journal:  Endocr Pract       Date:  2016-10       Impact factor: 3.443

5.  The prognostic potential of alpha-1 type I collagen expression in papillary thyroid cancer.

Authors:  Chang Huang; Ximing Yang; Li Han; Zhu Fan; Biyuan Liu; Chao Zhang; Tao Lu
Journal:  Biochem Biophys Res Commun       Date:  2019-05-22       Impact factor: 3.575

6.  Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases.

Authors:  Mübeccel Akdis; Simone Burgler; Reto Crameri; Thomas Eiwegger; Hiroyuki Fujita; Enrique Gomez; Sven Klunker; Norbert Meyer; Liam O'Mahony; Oscar Palomares; Claudio Rhyner; Nadia Ouaked; Nadia Quaked; Anna Schaffartzik; Willem Van De Veen; Sabine Zeller; Maya Zimmermann; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

Review 7.  The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Simona Piaggi; Michaela Luconi; Giulia Cantini; Stefania Gelmini; Giusy Elia; Ilaria Ruffilli; Alessandro Antonelli
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

8.  Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome.

Authors:  Pierpaolo Trimboli; Valentina Zilioli; Mauro Imperiali; Luca Giovanella
Journal:  Clin Chem Lab Med       Date:  2017-10-26       Impact factor: 3.694

Review 9.  The Immunobiology of the Interleukin-12 Family: Room for Discovery.

Authors:  Elia D Tait Wojno; Christopher A Hunter; Jason S Stumhofer
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 10.  Interleukin-12: clinical usage and molecular markers of cancer susceptibility.

Authors:  Arseniy E Yuzhalin; Anton G Kutikhin
Journal:  Growth Factors       Date:  2012-04-19       Impact factor: 2.511

View more
  1 in total

1.  Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration.

Authors:  Guangzhen Wu; Yingkun Xu; Chenglin Han; Zilong Wang; Jiayi Li; Qifei Wang; Xiangyu Che
Journal:  J Oncol       Date:  2020-12-30       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.